36 results about "Cell marker" patented technology

The invention relates to the technical field of biological information, in particular to a brain glioma microenvironment formation key molecular mechanism analysis method, which comprises the following steps: calling expression data to analyze a cell marker sequence to construct a segmentation interval, calculating a candidate factor expression direction to judge trend consistency, identifying expression aggregation difference to construct a split node section, and constructing a subsection; according to the method, partitions are constructed on the basis of marker expression syn-position, judgment is carried out in combination with candidate factor expression directions and marker trends, factor collaboration features are constructed according to the number of trends consistent times, and the semantic sorting information is generated by analyzing the channel change trends to generate drift scores, evaluating multi-label output stability screening key factors and analyzing literature word order positions. Identifying and expressing an aggregation and split structure, guiding a functional pathway to perform trend analysis in a scoring interval and construct a dynamic trajectory, judging label stability and empowerment according to pathway scoring difference, and determining a factor semantic position in combination with a literature word order structure to realize integrated support of regulation and control information and literature evidence.

1. The name of the design product: graphical user interface for computer cell marker gene statistics. 2. The use of the design product: the design product is used in electronic equipment to count cell marker genes. 3. The design points of the design product: the interface content of the graphical user interface. 4. The picture or photo that best shows the design points: front view. 5. The product involved in the design patent application is a graphical user interface, and the rear view, left view, right view, top view and bottom view are omitted. 6. Other circumstances that need to be explained: the interface of the product is a graphical user interface for cell marker gene statistics, which is a structured design of species, system, tissue, cell type and visualization design of species structure. The first column is species, the second column is system and tissue, the third column is cell type, and the fourth column is typical marker statistics of cells. Users can filter species, system, tissue and cell type through this interface, and finally view the typical marker statistics chart of cells.

The invention relates to the technical field of biomedicine detection, and discloses a tumor cell marker detection system for predicting the activation state of intracellular protein kinase. Comprising a marker detection module used for qualitatively detecting epithelial cell markers, mesenchymal cell markers, cell polarity markers and extracellular matrix related markers in tumor cells; the data processing module is used for performing cross validation on an epithelial cell marker, a mesenchymal cell marker, a cell polarity marker and an extracellular matrix related marker; the dynamic weighting module is used for performing dynamic weighting on different markers based on a complex system theory, and endowing epithelial cadherin with a higher weight; and the judgment module is used for determining whether epithelial intercellular substance transformation occurs or not according to the dynamically weighted marker data, and predicting the activation state of intracellular phosphoinositide 3-kinase alpha and the invasiveness of tumor cells based on the determination result of the epithelial intercellular substance transformation.

The invention discloses a method and a system for analyzing immune cell change of an HER2 variant lung cancer patient. The method comprises the following steps: collecting a peripheral blood sample and carrying out single-cell RNA (Ribonucleic Acid) sequencing; performing quality control, standardization processing, dimensionality reduction and clustering analysis on the sequencing data; carrying out immune cell subset annotation on the clustering result based on a preset immune cell marker; analyzing cell communication modes among different immune cell subpopulations by using a ligand-receptor database; performing quantitative statistics on the proportion of various immune cells based on sample grouping; and further performing subpopulation fine analysis, quasi-time sequence trajectory reconstruction and metabolic pathway activity evaluation on the CD8 + T cells to construct a comprehensive immune cell map. According to the method, the multi-dimensional characteristics of the peripheral blood immune cells can be presented at high resolution, and the comprehensive analysis of the functional state, the communication network and the metabolic activity of the immune cells is realized. According to the system and the device, automatic operation and visual display of the method can be realized. According to the invention, the immune monitoring efficiency can be improved, and an effective tool is provided for immune treatment effect evaluation and disease mechanism research.

A modified cell is provided that expresses (a) a chimeric antigen receptor targeting GPC3 and / or CD19, and (b) a multispecific antigen binding protein, variant or binding fragment thereof that binds to one or more targets, comprising a first antigen binding protein, variant or binding fragment thereof that binds to EpCAM (epithelial cell adhesion molecule), and a second antigen binding protein, variant or binding fragment thereof, which binds to an immune cell marker, wherein the first antigen binding protein, variant or binding fragment thereof, which binds to EpCAM comprises a heavy chain variable region and / or a light chain variable region comprising a sequence as disclosed herein. Also disclosed are methods of generating / generating cells as disclosed herein and methods of treating with cells as disclosed herein.

The invention discloses a vascular endothelial cell as well as a preparation method and application thereof. The preparation method comprises the following steps: inoculating induced pluripotent stem cells into a culture medium containing an ROCK signal channel inhibitor for culturing, and inducing the cultured induced pluripotent stem cells by using a culture medium containing a Wnt signal channel activator and a BMP signal channel activator, so that the induced pluripotent stem cells are differentiated into mesoderm cells; inducing the mesoderm cells by using a culture medium containing a vascular endothelial growth factor and a cAMP signaling pathway agonist, so that the mesoderm cells are differentiated into endothelial coarse cells; and performing positive sorting of the endothelial cell marker CD144 on the endothelial coarse cells to obtain purified vascular endothelial cells. The induction path of the method is clear and efficient, the period is short, the vascular endothelial cell population with high purity, complete vascular barrier function and mature phenotype can be obtained, and the cell population can be applied to construction of a vascular network in a gel matrix.

The invention provides application of OPC-like cell detection in prediction of glioblastoma with epilepsy. Specifically, the invention provides an application of a detection reagent of OPC-like cell markers PDGFRA and EGFRvIII in prediction of epilepsy of people with glioblastoma. The invention has an application prospect in the field of diagnosis and treatment of diseases of glioblastoma with epilepsy.

Provided is a method for measuring a highly accurate and quantitative index that can be used for cancer diagnosis and therapeutic effect evaluation. The measurement method includes: a detection step for detecting, from blood collected from a subject, aggregates in which a central region exhibiting characteristics of enucleated cancer cells is surrounded by a plurality of cells that are white blood cells; and a counting step for counting the number of the aggregates detected in the detection step. The central region may exhibit at least one among: a first feature in which a detection reaction by a cancer epithelial marker is positive and a nucleus is not recognized; a second feature in which a detection reaction by a cancer epithelial marker is negative, a nucleus is not recognized, and a detection reaction by a leukocyte-lineage cell marker is positive; and a third feature in which a detection reaction by a cancer epithelial marker is negative, a nucleus is not recognized, and a detection reaction by a leukocyte-lineage cell marker is negative.

The invention provides a nipple discharge cytological examination method, and belongs to the technical field of nipple discharge cytological examination. Calculating an optimal detection parameter combination including a dyeing time parameter, an antibody concentration parameter, a cell counting threshold parameter, a fluorescence intensity threshold parameter and a cell morphology evaluation weight parameter, performing pasteurization and HE dyeing treatment on the nipple discharge smear according to the optimal parameter combination, and observing cell morphology characteristics. A multi-parameter flow cytometry is used for analyzing cell marker expression and cell cycle distribution, a fluorescence in situ hybridization technology is used for detecting chromosome abnormalities such as HER2 gene amplification, TOP2A gene change and chromosome No.17 centromere number change, and a diagnosis result risk grading system is established. The technical problem that in the prior art, nipple discharge cytology examination is not high in accuracy is solved.

A quality control slide of a cell counting device, includes: a base layer which is capable of transmitting light therethrough; a thin film layer which is formed on top of the base layer; a fluorescent layer which is formed on the thin film layer and expresses fluorescence by means of light transmitted through the base layer; and at least one cell marking part which is formed by piercing the thin film layer and through which the expressed fluorescence passes so as to be recognized as a cell.

To provide an improved verification method for verifying the performance of a fluorescence-based analysis system.SOLUTION: (a) negatively staining cells in a first portion of a standard sample comprising target cells expressing a target cell marker; (b) positively staining target cells in a second portion of the standard sample; (c) passing the first and second portions of the standard sample through an instrument to obtain a fluorescence measurement indicative of target cell concentration; (d) based on the fluorescence measurement obtained in (c), each diluted sample having a nominal concentration of target cells, each nominal cell concentration being greater than the concentration of target cells indicated by the fluorescence measurement of the negatively stained first portion in (a); Preparing a dilution series comprising a plurality of diluted samples, wherein the nominal concentration in each diluted sample is different from the nominal concentration in each of the remaining diluted samples; (e) passing the dilution series of (d) through the instrument and obtaining a fluorescence measurement; and (f) comparing the nominal cell concentration of (d) and the fluorescence measurement of (e) for each diluted sample to quantify the performance of the staining method in the instrument.SELECTED DRAWING: Figure 1

This application relates to methods for classifying cell markers. Methods and systems for classifying cell markers, such as identifying signaling cell markers, are disclosed herein. In some embodiments, the method includes: obtaining sequencing data of a barcoded target created using a barcoded target within a cell, wherein the barcode contains both cellular and molecular markers. After classifying these cellular markers, a minimum value of the second derivative graph of the cumulative sum can be determined. Using these methods, based on the number of molecular markers with different sequences associated with the cellular marker and a cellular marker threshold, the cellular marker can be classified as a signaling cell marker or a noise cell marker.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

The invention discloses an application of a novel peptide UPCP in preparation of a medicine for treating and / or preventing psoriasis. Belongs to the technical field of biological medicine. The application discloses the treatment effect of the novel peptide UPCP on psoriasis for the first time, and researches find that the novel peptide UPCP can effectively relieve symptoms of a psoriasis model induced by LSP, TNF alpha and M2 in an in-vitro cell experiment, significantly down-regulate the expression level of psoriasis cell markers, significantly reduce the transcriptional level of psoriasis-related inflammatory factors, and improve the psoriasis treatment effect. The condition of excessive proliferation of HaCaT cells is effectively reduced. In in-vivo experiments, psoriasis symptoms such as skin desquamation, hyperplasia, erythema, thickening and splenomegaly of an imiquimod-induced psoriasis mouse model can be effectively relieved, the effect of treating psoriasis is achieved, and a new theoretical basis and intervention means are provided for clinical treatment of psoriasis.

The present invention provides a method for cell analysis, comprising: preparing a blood sample comprising nucleated cells having surface, cytoplasmic or nuclear antigens (markers); antibody staining the cell markers; fixing and permeabilising the cells; FISH probe hybridising to chromosomes in the cells; performing imaging flow cytometry on the cells; analysing data obtained from performing imaging flow cytometry; and diagnosing, prognosing or monitoring a medical condition based on the data analysis.

An analysis system for analyzing an image of fluorescently labeled circulating epithelial cells includes at least a processor. The processor executes a processing procedure, wherein the processing procedure includes steps of: detecting boundaries of multiple cell areas from the image; measuring fluorescence signal intensity of each cell area to calculate expression levels of various cell markers of each cell area; and determining marker statuses of various cell markers of each cell area according to the expression levels of various cell markers of each cell area.

The invention provides a targeting exosome for hair regeneration and a preparation method thereof. The method comprises the following steps: separating dermal mastoid cells with a cell marker CD133 from a hair follicle strain of a healthy donor, and culturing the dermal mastoid cells in a laboratory conforming to a Taiwan GTP cell preparation factory domain in China in a heterologous and serum-free environment. Then, a culture solution containing exosomes is collected from the cell culture solution, and the multiple exosomes have surface markers such as CD9, CD63 and CD81; and finally, separating, purifying and concentrating the exosome from the culture solution by utilizing a tangential flow filtration system method or a size exclusion chromatography method and other technologies to obtain the final targeting exosome freeze-dried powder product. The invention also provides a liquid hair growth preparation prepared from the exosome product.

The invention discloses a single-cell multi-dimensional mass spectrum data processing method, and relates to the technical field of data processing. The method comprises the steps that at least two original secondary spectrograms are acquired, the secondary spectrograms comprise ion mobility mass spectrum data frames of at least two continuous secondary spectrogram acquisition windows, the ion mobility mass spectrum data frames comprise mass-to-charge ratios and ion mobility values of target objects, and the target objects comprise metabolite ions and single cell marker ions; carrying out single cell ionization event identification processing on each original secondary spectrogram, and screening candidate secondary spectrograms from at least two original secondary spectrograms; determining a marker ion mobility mass spectrum data frame of the single cell marker ion corresponding to each secondary spectrogram acquisition window where the metabolite ion is located according to the acquisition mode of the original secondary spectrogram and the candidate secondary spectrogram; and summing the secondary spectrograms corresponding to the marker ion mobility mass spectrum data frames of the metabolite ions to obtain a target secondary spectrogram of the metabolite ions, so that the identification accuracy of the single cell metabolite can be improved.

The invention relates to the field of biological medicine, and discloses an anti-aging AAV virus vector of a targeted FAP cell overexpression DUSP1 plasmid, which is characterized by being obtained by co-transfecting an AAV-293 cell with a vector plasmid carrying a DUSP1 gene, a pAAV-RC vector plasmid and a pHelper vector plasmid, and then purifying the co-transfected AAV-293 cell. According to the scheme, an AAV-293 cell is co-transfected by a carrier plasmid carrying a DUSP1 gene, a pAAV-RC carrier plasmid and a pHelper carrier plasmid to obtain an AAV vector, the AAV vector carries a promoter region of an FAP cell marker TCF4 to specifically target the FAP cell and deliver a DUSP1 gene sequence into the FAP cell, so that the purpose of overexpressing DUSP1 protein in the FAP cell is achieved, the aging of the FAP cell is improved, and the DUSP1 protein can be used for treating the FAP cell. The amyotrophy progress is inhibited; the life of old mice is prolonged.

Embodiments of the present application provide a positive cell detection method, system, device and medium, relating to the technical field of medical detection, the method comprising: obtaining sample cells, and marking cells with two signal points in the sample cells as target cells; obtaining the signal interval between the two signal points in each target cell, and dividing the target cells according to a plurality of preset signal intervals to obtain a plurality of division results; obtaining the clinical diagnosis result corresponding to the sample cells, and determining a target result from the plurality of division results according to the clinical diagnosis result; determining a target signal interval from the plurality of preset signal intervals according to the target result, and taking the target signal interval as the positive cell detection standard. The present application defines the detection standard of positive cells, and improves the accuracy and efficiency of positive cell detection.

The present application relates to methods for cell marker classification. Disclosed herein are methods and systems for classifying cell markers, e.g., identifying signal cell markers. In some embodiments, the method comprises obtaining sequencing data of barcoded targets created using barcoding of targets in cells with barcodes, wherein the barcodes comprise cell markers and molecular markers. After ranking the cell markers, the minimum of the cumulative and the second derivative plot of the cumulative plot can be determined. Using these methods, the cell marker can be classified as a signal cell marker or a noise cell marker based on the number of molecular markers with different sequences associated with the cell marker and a cell marker threshold.

According to the cell subset classification method based on the plant single cell transcriptome marker gene, the electronic equipment and the storage medium, original genes with low-quality expression are removed based on the gene expression matrix, the marker gene set is obtained, redundant information is effectively removed, key cell markers are accurately recognized, and the classification efficiency is improved. Then, low-dimensional cell expression vectors corresponding to the plant single cells are determined on the basis of the marker gene set, and training is carried out on the basis of the low-dimensional cell expression vectors corresponding to the plant single cells and the cell subset categories to which the plant single cells belong, so that a cell subset classification model is obtained; and acquiring the low-dimensional cell expression vector of the to-be-classified plant cells based on the marker gene set, and determining the cell subpopulation to which the to-be-classified plant cells belong according to the low-dimensional cell expression vector of the to-be-classified plant cells and the cell subpopulation classification model, thereby realizing accurate classification of the to-be-classified plant cells.

Provided herein is a bispecific antibody comprising an IgG antibody binds specifically to a B-cell marker; and an anti-CD16A VHH covalently linked to C-terminus of each of two heavy chains of the IgG antibody for treatment of an autoimmune disease.

This invention discloses a cell marker gene for maintaining the ion environment in silk-secreting insects. KCNQ Identification and application of marker genes for maintaining ion environment in silk-secreting insects KCNQ The gene is as shown in a) or b) below: a) the nucleotide sequence is as shown in SEQ ID No. 1; b) a protein encoding the amino acid sequence shown in SEQ ID No. 2, or a protein encoding a potassium channel activity obtained by substitution, deletion, and / or addition of one or more amino acid residues. This invention has discovered... KCNQ The present invention maintains cell-specific high expression in an ionic environment. KCNQ The gene is homologously conserved in various silk-secreting insects and is specifically expressed in the anterior silk gland. It can be used for the precise identification of anterior silk gland cell types in silk-secreting insects, the molecular improvement of silk fiber properties, and the development of multifunctional silk protein materials, which has important application value.

The invention belongs to the technical field of organoid models, and particularly relates to a method for screening drugs for treating chronic obstructive pulmonary disease based on a rat lung organoid model and application of the method. Culturing the rat lung tissue subjected to enzymolysis into an organoid, identifying cell markers such as type I alveolar epithelial cells, type II alveolar epithelial cells, macrophages and the like in the lung organoid through an immunofluorescence and / or immunohistochemical method, and confirming the structural and functional integrity of the organoid; establishing a rat lung organ COPD model by using the cigarette smoke extract; then, a drug to be screened acts on the model, the drug sensitivity is evaluated by detecting cell activity, the optimal compatibility of effective components is screened in combination with an orthogonal test, then the apoptosis condition of organoid cells after the drug acts is detected by adopting flow cytometry, and finally, the drug with treatment potential is determined. The method can efficiently and accurately realize integration of drug sensitivity detection and active ingredient compatibility screening, and provides a reliable in-vitro experiment system for research and development of COPD treatment drugs.

The invention discloses an induced differentiation method of sebaceous gland cells, which comprises the following specific steps: adding epidermal stem cells into an induction culture medium, and carrying out induced culture for 5-7 days to obtain the sebaceous gland cells, wherein the adopted induction culture medium is not added with insulin and specifically comprises the following components: 50% of a keratinocyte culture medium, 50% of a sebaceous gland cell culture medium, 1% of antibiotics, 20-40 ng / mL of EGF, 10-40 ng / mL of KGF and 5-20 ng / mL of rosiglitazone. Growth factors EGF and KGF and rosiglitazone are simultaneously added into the induction culture medium, insulin is completely not added, normal division and proliferation of cells are guaranteed, and sebaceous gland cells which are good in growth state and high in differentiation degree are obtained in a short culture period; compared with SZ95, the expression quantities of various sebaceous gland cell markers are similar.

This invention relates to the fields of environmental toxicology and organoid technology, and particularly to a method for assessing the toxicity of environmental microplastic exposure based on testicular organoids. The method includes: processing waste testicular tissue into a single-cell suspension, the single-cell suspension comprising supporting cells, germ cells, and interstitial cells; seeding the single-cell suspension onto a biomimetic hydrogel scaffold for culture to obtain mature testicular organoids, which are then cultured in a target microplastic exposure solution to establish a microplastic exposure model; determining the raw values ​​of toxicity assessment indicators corresponding to the microplastic exposure model, including: morphological score data, grayscale values ​​of cell marker expression, DNA damage indicators, testosterone secretion levels, and cytotoxicity indicators; calculating a comprehensive toxicity score based on the raw values ​​of each toxicity assessment indicator, and assessing the reproductive toxicity risk level of the target microplastic exposure based on the comprehensive toxicity score. This application can improve the accuracy of assessing the reproductive toxicity risk level of microplastic exposure.

The invention provides identification and application of a left heart disease-related pulmonary arterial hypertension pulmonary artery part endothelial mesenchymal transformation subgroup, and finds that according to the ratio of expression levels of endothelial cell markers (such as VWF and CD31) and mesenchymal cell markers (such as alpha-SMA, DCN and TAGLN) in an EndMT cell subgroup, the expression level of the endothelial cell markers (such as VWF and CD31) in the EndMT cell subgroup is determined, and the expression level of the mesenchymal cell markers (such as alpha-SMA, DCN and TAGLN) in the EndMT cell subgroup is determined. And the expression levels of TGF-beta1, TNFRSF1A, CXCL12, CCL14, CD74, TGFBR2 and CD44 in the EndMT cell subset can (i) be used for typing patients of PH-LHD according to different periods of mesenchymal transformation of endothelial cells; and / or (ii) is used for judging whether a patient suffering from the left heart disease related pulmonary hypertension (PH-LHD) is suitable for adopting a CD74 inhibitor, and / or a CD44 inhibitor is used as a target spot for treating the left heart disease related pulmonary hypertension (PH-LHD).

Conventionally, tertiary lymphoid structure identification is performed manually by pathologists. However, identifying TLS is a subjective procedure that results in issues of reproducibility caused by different pathologists making different decisions. The present invention relates to a computer-implemented method to provide decision support to clinicians and improve the accuracy and efficiency of TLS detection, preferably mature TLS detection in an image of a tumor tissue section previously stained with B-cell, T-cell, follicular B-cell and mature dendritic cell markers by applying a trained machine-learning model.